Impact News +++ DAX-Anleger warten auf Fed-Entscheid - Beiersdorf, Commerzbank, Nordex, Schaeffler, Siltronic und... (Der Aktionaer) +++ THYSSENKRUPP Aktie +3,28%

CO-DIAGNOSTICS Aktie

>CO-DIAGNOSTICS Aktienkurs

0.458 EUR -13.6% (Tradegate)

Ask: 0.535 EUR / 2000 Stück

Bid: 0.45 EUR / 2000 Stück

Tagesumsatz: 2800 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

Aktie über LYNX handeln

Intraday

1 Jahr

>CO-DIAGNOSTICS Performance

1 Woche: +93,3%

1 Monat: +94,0%

3 Monate: +108,0%

6 Monate: +16,9%

1 Jahr: -54,8%

laufendes Jahr: -24,6%

>CO-DIAGNOSTICS Aktie

Name:

CO-DIAGNOSTICS DL-,001

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US1897631057 / A2DU6V

Symbol/ Ticker:

C97 (Frankfurt) / CODX (NASDAQ)

Kürzel:

FRA:C97, ETR:C97, C97:GR, NASDAQ:CODX

Index:

Webseite:

https://codiagnostics.com..

Profil:

Co-Diagnostics Inc. is a molecular diagnostics com..
>Volltext..

Marktkapitalisierung:

11.55 Mio. EUR

Unternehmenswert:

1.67 Mio. EUR

Umsatz:

0.48 Mio. EUR

EBITDA:

-32.15 Mio. EUR

Nettogewinn:

-30.52 Mio. EUR

Gewinn je Aktie:

-0.95 EUR

Schulden:

1.44 Mio. EUR

Liquide Mittel:

9.43 Mio. EUR

Operativer Cashflow:

-27.56 Mio. EUR

Bargeldquote:

3.6

Umsatzwachstum:

-91.94%

Gewinnwachstum:

12.89%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

CO-DIAGNOSTICS, CO DIAGNOSTICS

Letzte Datenerhebung:

17.09.25

>Kennzahlen

Aktien/ Unternehmen:

Aktien: 38.52 Mio. St.

Frei handelbar: 91%

Leerverk. Aktien: 4.26%

Rückkaufquote: -6.52%

Mitarbeiter: 132

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Buy

Kursziel: 2587.14%

Bewertung:

KGV: -

KGV lG: -

KUV: 20.52

KBV: 0.33

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -231.3%

Gewinnmarge: -6321%

Operative Marge: -6882.12%

Managementeffizenz:

Gesamtkaprendite: -56.6%

Eigenkaprendite: -63.4%

>Peer Group

Es sind 601 Aktien bekannt.

>CO-DIAGNOSTICS Chart & Kurs - NASDAQ

>CO-DIAGNOSTICS News

16.09.25 - 15:33	Co-Diagnostics, Inc. Signs Strategic MOU with Partner in Kingdom of Saudi Arabia to Introduce Co-Dx™ PCR Platform to Middle East (PR Newswire)
	The Memorandum of Understanding includes the formation of a Joint Venture in the Kingdom of Saudi Arabia for manufacturing and distribution of the Company's upcoming Co-Dx™ PCR platform and other Co-Dx IP SALT LAKE CITY, Sept. 16, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX)......

11.09.25 - 15:30	Co-Diagnostics, Inc. Performs Analysis of Chikungunya Co-Primers® to Confirm Reactivity Against Known Virus Strains (PR Newswire)
	SALT LAKE CITY, Sept. 11, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has performed an in silico analysis of......

09.09.25 - 15:33	Co-Diagnostics, Inc. Honored at Utah Business 2025 Innovation Awards Summit (PR Newswire)
	SALT LAKE CITY, Sept. 9, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that Co-Dx™ was an honoree at the Utah Business......

18.08.25 - 15:33	Co-Diagnostics, Inc. to Host Booth at 17th Next Generation Dx Summit in Washington, D.C. (PR Newswire)
	SALT LAKE CITY, Aug. 18, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it will be hosting a booth at the 17th......

15.08.25 - 01:45	Co-Diagnostics outlines clinical trial timeline and targets mid-2026 commercialization for PCR platform (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

15.08.25 - 01:00	Co-Diagnostics, Inc. (CODX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
	CoDiagnostics (CODX) delivered earnings and revenue surprises of +8.00% and -45.67%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?...

14.08.25 - 23:36	Co-Diagnostics CODX Earnings Call Transcript (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

14.08.25 - 23:00	Co-Diagnostics Sales Plunge 93 Percent (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

14.08.25 - 22:09	Co-Diagnostics GAAP EPS of -$0.23 beats by $0.02, revenue of $0.16M misses by $0.14M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

14.08.25 - 22:03	Co-Diagnostics, Inc. Reports Second Quarter 2025 Financial Results (PR Newswire)
	SALT LAKE CITY, Aug. 14, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended June 30, 2025. Second Quarter 2025......

31.07.25 - 15:33	Co-Diagnostics, Inc. Announces Second Quarter 2025 Earnings Release Date and Webcast (PR Newswire)
	SALT LAKE CITY, July 31, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its second quarter 2025 financial results on Thursday,......

15.07.25 - 15:30	Co-Diagnostics, Inc. to Host Booth at WHX Kuala Lumpur on July 16-18, 2025 (PR Newswire)
	SALT LAKE CITY, July 15, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth at WHX......

14.05.25 - 15:33	Co-Diagnostics, Inc. to Participate in D. Boral Inaugural Global Conference (GlobeNewswire EN)
	Salt Lake City, Utah, May 14, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that they will be participating in the D. Boral Capital (“DBC”) Inaugural Global Conference on May 14, 2025 in New York City....

09.05.25 - 02:30	Co-Diagnostics, Inc. (CODX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
	CoDiagnostics (CODX) delivered earnings and revenue surprises of 27.27% and 86.84%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?...

08.05.25 - 22:36	Co-Diagnostics GAAP EPS of -$0.24 beats by $0.03, revenue of $0.05M misses by $0.14M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

08.05.25 - 22:03	Co-Diagnostics, Inc. Reports First Quarter 2025 Financial Results (GlobeNewswire EN)
	SALT LAKE CITY, May 08, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended March 31, 2025....

07.05.25 - 23:36	Co-Diagnostics Q1 2025 Earnings Preview (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

07.04.25 - 20:00	Summary Notice of Pendency of Class Action in Stadium Capital LLC v. Co-Diagnostics, Inc., et al. (PR Newswire)
	PHILADELPHIA, April 7, 2025 /PRNewswire/ -- The following release was issued by RG/2 Claims Administration LLC, as Settlement Administrator. UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK STADIUM CAPITAL LLC, on behalf of itself and all others similarly situated v.......

28.03.25 - 01:30	Co-Diagnostics, Inc. (CODX) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
	CoDiagnostics (CODX) delivered earnings and revenue surprises of -5.88% and 60.79%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?...

27.03.25 - 23:51	Co-Diagnostics targets 2025 clinical evaluations for TB and HPV tests in India and South Africa (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Die Siegesgöttin ist nach verlorenen Kriegen ein Friedensengel. - Kurt Tucholsky

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram